ConcertAI
Founded Year
2017Stage
Series C | AliveTotal Raised
$320MValuation
$0000Last Raised
$150M | 4 yrs agoRevenue
$0000Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-47 points in the past 30 days
About ConcertAI
ConcertAI specialises in generative and agentic artificial intelligence (AI) solutions within the life sciences and healthcare sectors. The company offers a suite of products that utilise real-world data and AI to support clinical research, facilitate clinical trials, and provide insights for oncology care. ConcertAI's services are directed towards life sciences and healthcare organisations looking to advance translational medicine. ConcertAI was formerly known as Concerto HealthAI. It was founded in 2017 and is based in Cambridge, Massachusetts.
Loading...
ESPs containing ConcertAI
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The real-world data providers market offers a variety of value propositions to the pharmaceutical industry, drug labs, and healthcare organizations. It provides access to diverse patient populations, longitudinal real-world data, and patient-powered or EHR-powered controls that can replicate real-world scenarios. This can help shorten drug development timelines, reduce patient recruitment burdens …
ConcertAI named as Outperformer among 15 other companies, including IQVIA, Tempus, and Datavant.
Loading...
Research containing ConcertAI
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned ConcertAI in 3 CB Insights research briefs, most recently on Aug 21, 2024.
Aug 21, 2024
The clinical trials tech market map
Expert Collections containing ConcertAI
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ConcertAI is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,297 items
AI 100 (All Winners 2018-2025)
100 items
The winners of the 4th annual CB Insights AI 100.
Conference Exhibitors
5,302 items
Digital Health 50
150 items
The winners of the second annual CB Insights Digital Health 150.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
ConcertAI Patents
ConcertAI has filed 1 patent.
The 3 most popular patent topics include:
- artificial neural networks
- classification algorithms
- machine learning
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/29/2021 | Machine learning, Artificial neural networks, Classification algorithms, Machine learning algorithms, Statistical classification | Application |
Application Date | 10/29/2021 |
|---|---|
Grant Date | |
Title | |
Related Topics | Machine learning, Artificial neural networks, Classification algorithms, Machine learning algorithms, Statistical classification |
Status | Application |
Latest ConcertAI News
Nov 4, 2025
the appointment of Sriram Krishnan, Ph.D. as the company's new Chief Product Officer. A recognized leader in healthcare AI and digital health, Krishnan joins the company with decades of experience in building and commercializing products with patient impact. “As Target RWE continues to expand our real-world evidence and data-driven research capabilities, Sriram's deep expertise and passion for leveraging technology to improve the delivery of care will be invaluable.” “Sriram's proven success in applying advanced technologies to improve patient outcomes aligns perfectly with our mission and makes him the ideal individual to lead our product team,” said Ed Seguine, Chief Executive Officer of Target RWE. “As Target RWE continues to expand our real-world evidence and data-driven research capabilities, Sriram's deep expertise and passion for leveraging technology to improve the delivery of care will be invaluable.” Prior to joining Target RWE, Krishnan served as Executive Vice President of Products at ConcertAI, where he built and scaled a global organization focused on real-world data, advanced analytics, and AI-driven clinical and commercial solutions. Most recently, Krishnan was Chief Product Officer at Carenostics , an early-stage company developing AI-driven clinical decision support tools for chronic disease management, which was recognized as a “Rising Star in AI” at HLTH. During his career, he has also held senior leadership roles at Siemens Healthineers KPMG and Deloitte Dr. Krishnan holds 28 issued patents and has authored more than 30 scientific publications spanning machine learning and digital health. He received his Ph.D. in Biomedical Engineering from the University of Michigan. “I am thrilled to join Target RWE at this important inflection point in the company's evolution,” said Sriram Krishnan, Target RWE, Chief Product Officer. “Target RWE is at the forefront of applying new approaches to generate real world evidence that can meet the demands of today's rapidly changing healthcare system. I am honored to join a team of such talented individuals dedicated to translating data into insights for the betterment of patient care.” About Target RWE Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy. Visit our website to learn more: https://targetrwe.com/
ConcertAI Frequently Asked Questions (FAQ)
When was ConcertAI founded?
ConcertAI was founded in 2017.
Where is ConcertAI's headquarters?
ConcertAI's headquarters is located at 1120 Massachusetts Avenue, Cambridge.
What is ConcertAI's latest funding round?
ConcertAI's latest funding round is Series C.
How much did ConcertAI raise?
ConcertAI raised a total of $320M.
Who are the investors of ConcertAI?
Investors of ConcertAI include Sixth Street, AllianceBernstein, Declaration Partners, SymphonyAI, Maverick Ventures Israel and 6 more.
Who are ConcertAI's competitors?
Competitors of ConcertAI include Mango Sciences, Aetion, Mendel AI, Zephyr AI, Holmusk and 7 more.
Loading...
Compare ConcertAI to Competitors
Owkin is an AI biotechnology company that employs artificial intelligence to improve drug discovery and development in the biopharmaceutical sector. The company specializes in AI-based identification of new treatments, clinical trial optimization, and diagnostic tool creation, while ensuring patient privacy through federated learning techniques. Owkin serves the biopharma and academic research communities. It was founded in 2016 and is based in New York, New York.
TriNetX is a network that focuses on real-world research in the life sciences and healthcare sectors. The company provides a platform for access to federated electronic health records (EHR), datasets, and consulting services aimed at clinical trial design, operations, and drug safety. TriNetX serves healthcare organizations and life sciences industries. It was founded in 2013 and is based in Cambridge, Massachusetts.
Saama Technologies provides life science solutions within the healthcare technology sector. The company offers artificial intelligence (AI) powered solutions that improve clinical trials and commercial operations in the life sciences industry. Saama serves the healthcare and pharmaceutical sectors by providing tools that support the development and delivery of therapies. It was founded in 1997 and is based in Campbell, California.
Insitro is a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology. The company has a machine learning platform that combines in vitro cellular data with human clinical data to identify insights and interventions in metabolism, oncology, and neuroscience. Insitro's approach uses technology to model disease states and design therapeutic interventions. It was founded in 2018 and is based in South San Francisco, California.
OM1 operates as a technology and data company providing data and insights within the healthcare sector. The company focuses on personalized medicine, evidence generation, and real-world evidence (RWE) research, using artificial intelligence (AI) platforms and longitudinal data. OM1 offers solutions including digital phenotyping, prospective and retrospective evidence generation, and analytics services. OM1 was formerly known as Better Outcomes. It was founded in 2015 and is based in Boston, Massachusetts.
Promptly Health offers real-world evidence solutions within the healthcare sector. The company provides services that include generating knowledge from clinical, socio-economic, and claims data, as well as collecting longitudinal patient-reported data and digital biomarkers. Promptly Health serves life sciences, healthcare providers, and healthcare payers. It was founded in 2017 and is based in Porto, Portugal.
Loading...